Alpha memo: resveratrol exercise disease-model-to-human boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename or reframe the title to reflect what the receipts actually compare: a mouse AD cardiovascular signal vs. a healthy-aged-men skeletal-muscle signal — not a generic 'disease-model-to-human' boundary.
2. Explicitly acknowledge that Receipt 1 and Receipt 2 differ on tissue (heart/aorta vs. skeletal muscle), species (mouse vs. human), disease status (3xTg AD vs. healthy), and endpoint class (cardiovascular function/structure vs. metabolic/inflammatory), so the 'transfer' claim is honest about not being able to attribute the split to any single axis.
3. Clarify from the Receipt 1 excerpt whether resveratrol alone, exercise alone, or the combination produced the cardiac benefit, so the resveratrol-specific transfer claim is source-grounded.

Major issues

• Title/source alignment mismatch: title frames 'disease-model-to-human boundary' but Receipt 1 is a mouse AD cardiovascular phenotype study and Receipt 2 is healthy aged men — Receipt 2 is not a 'disease model' counterpart and Receipt 1 is not a 'human' study, so the boundary the title promises is not actually crossed by the receipt pair.
• The comparison is not apples-to-apples: Receipt 1 measures cardiac/aortic structure and function in 3xTg AD mice; Receipt 2 measures skeletal muscle metabolic/inflammatory markers in healthy aged men. The memo treats 'resveratrol/exercise positive in mice, exercise-only positive in men' as a transfer boundary, but the endpoints, tissues, species, and health status all differ simultaneously, so the contrast does not isolate a translation failure.

Minor issues

• The excerpt for Receipt 1 suggests resveratrol and exercise together (not independently) drove the cardiac benefit; the memo does not clarify whether resveratrol alone was sufficient in the mouse study, weakening the 'resveratrol fails to translate' framing.
• Receipt 1 is 6 years old relative to a 2025 alpha-memo context but within the 5-year window only if dated 2021+; 2019 is older than ideal but acceptable.
• Several prose sections repeat the same alpha sentence verbatim rather than integrating.

Reviewer note

The memo correctly identifies a real contrast between two receipt-owned findings: a mouse AD study reporting combined resveratrol+exercise benefits on cardiac/aortic outcomes, and a human aged-men study reporting exercise-but-not-resveratrol benefits on skeletal muscle metabolic/inflammatory markers. Both citations exist, are recent enough, and are accurately represented at the title/DOI level. However, the title overpromises a 'disease-model-to-human boundary' when Receipt 2 is not a disease model and Receipt 1 is not a human study; the actual contrast is across species, tissue, disease status, and endpoint simultaneously, and the memo's own limitations section concedes it cannot isolate the driving axis. The 'bounded contrast' axes and 'falsifier' are reasonable but the central claim — that the Receipt 1 signal does not transfer — is not cleanly supported because Receipt 1 did not isolate resveratrol alone, and the endpoints are non-comparable. Recommend revise to rename the boundary more accurately and to acknowledge the multi-axis conflation explicitly.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis